Alto Neuroscience director granted 10,958 stock options

Alto Neuroscience, Inc. director Christopher Nixon Cox received a grant of stock options for 10,958 shares of common stock at an exercise price of $24.63 per share.

Rhea-AI Filing Summary

Alto Neuroscience, Inc. director Christopher Nixon Cox received a grant of stock options for 10,958 shares of common stock at an exercise price of $24.63 per share. These options vest on the earlier of one year from grant or the company’s next annual meeting, provided he continues in service, and were issued under the non-employee director compensation policy without any cash payment from him. Following this grant, he holds 10,958 stock options directly.

Insider Trade Summary

Grant/Award: 10,958 shares

Grant/Award 1 txn

Insider Cox Christopher Nixon

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	10,958	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 10,958 contracts (Direct)

Footnotes (2)

1. F1. The shares underlying the option shall vest on the earlier of the one-year anniversary of the date of grant and the date of Issuer's next Annual Meeting following the date of grant, subject to the Reporting Person's continuous service through such vesting date.
2. F2. This option was issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy, and was not sold to the Reporting Person. As such, the Reporting person did not pay any consideration for the derivative securities.

Key Figures

Options granted: 10,958 options Exercise price: $24.63 per share Post-transaction options held: 10,958 options +2 more

5 metrics

Options granted 10,958 options Stock Option (right to buy) grant on May 12, 2026

Exercise price $24.63 per share Conversion or exercise price for granted options

Post-transaction options held 10,958 options Total derivative securities following transaction

Expiration date May 11, 2036 Option expiration for the granted stock options

Vesting condition Earlier of 1-year from grant or next annual meeting Subject to continuous service through vesting date

Key Terms

Stock Option (right to buy), Non-Employee Director Compensation Policy, derivative securities, continuous service

4 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

Non-Employee Director Compensation Policy financial

"issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy"

derivative securities financial

"did not pay any consideration for the derivative securities"

Financial contracts whose value is tied to the price or performance of another asset, such as a stock, bond, commodity, index, or currency; examples include options, futures and swaps. They matter to investors because they let you protect against price swings, bet on future moves or gain larger exposure with less upfront cash—like using a lever or insurance policy on an investment—so they can amplify gains and losses and help manage portfolio risk.

continuous service financial

"subject to the Reporting Person's continuous service through such vesting date"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Alto Neuroscience (ANRO) director Christopher Nixon Cox report on this Form 4?

Christopher Nixon Cox reported receiving a grant of 10,958 stock options to buy Alto Neuroscience common stock at $24.63 per share. The options were issued as director compensation and increased his directly held derivative position to 10,958 options after the transaction.

What is the strike price and size of the Alto Neuroscience (ANRO) options granted?

The grant consists of 10,958 stock options with an exercise price of $24.63 per share. Each option represents the right to purchase one share of Alto Neuroscience common stock if and when the option vests and is exercised in the future.

When do Christopher Nixon Cox’s Alto Neuroscience (ANRO) options vest?

The 10,958 stock options vest on the earlier of the one-year anniversary of the grant date or Alto Neuroscience’s next annual meeting. Vesting is conditioned on Christopher Nixon Cox’s continuous service as a non-employee director through the applicable vesting date.

Did Christopher Nixon Cox pay cash for the Alto Neuroscience (ANRO) stock options?

He did not pay cash for these derivative securities. The footnotes state the option was issued under Alto Neuroscience’s Non-Employee Director Compensation Policy, meaning it was granted as compensation and not sold to him for consideration at the time of the award.

How long do the newly granted Alto Neuroscience (ANRO) options remain exercisable?

The stock options expire on May 11, 2036, giving a long exercise window after vesting. After vesting, Christopher Nixon Cox may choose whether and when to exercise, subject to plan terms and this final expiration date disclosed in the filing.

How many Alto Neuroscience (ANRO) derivative securities does Christopher Nixon Cox hold after this grant?

After the reported grant, he holds 10,958 derivative securities in the form of stock options. This figure reflects his total directly owned options following the transaction, as disclosed in the Form 4’s post-transaction holdings field.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/14/2026 - 04:58 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cox Christopher Nixon

(Last) (First) (Middle)

C/O ALTO NEUROSCIENCE, INC.

650 CASTRO STREET, SUITE 450

(Street)

MOUNTAIN VIEW CALIFORNIA 94041

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Alto Neuroscience, Inc. [ ANRO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$24.63	05/12/2026		A		10,958		(1)	05/11/2036	Common Stock	10,958	$0(2)	10,958	D

Explanation of Responses:

1. The shares underlying the option shall vest on the earlier of the one-year anniversary of the date of grant and the date of Issuer's next Annual Meeting following the date of grant, subject to the Reporting Person's continuous service through such vesting date.

2. This option was issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy, and was not sold to the Reporting Person. As such, the Reporting person did not pay any consideration for the derivative securities.

Remarks:

	/s/ Erin R. McQuade, Attorney-in-Fact	05/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)